SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs Q3 earnings beat expectations, with traders highlighting rapid growth in its AI-computing business and Starlink. Bulls celebrated the results and ambitious growth outlook, while skeptics questioned the valuation and heavy infrastructure spending and noted the stocks muted reaction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results were broadly solid, but softer forward guidanceincluding a reduced advertising outlook and lower expected cash flowhas driven a sharp post-earnings selloff amid concerns about slowing growth. Traders are split between expecting further downside and viewing the drop as an overreaction to guidance despite the earnings beat.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue outlook and projected higher gross margins, citing AI-platform demand. Traders largely welcomed the surprise as evidence of strong AI-server demand and a possible boost to the broader AI trade, while others questioned whether the gains would hold amid persistent concerns about management, execution, and volatile price action.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of large Chinese orders for Nvidias export-compliant RTX PRO 5500 GPUs are fueling discussion, with traders pointing to strong demand but noting supply constraints and uncertainty over how much Nvidia can deliver. The stocks muted response has frustrated bulls, while others remain cautious amid broader concerns about AI spending, financing risks and recent weakness in chip stocks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th death event that triggers final analysis of its Phase 3 REGAL trial of GPS; the last disclosed count was 78, and the event has not been confirmed in the discussion. The CEOs next chapter remarks have also fueled speculative buyout talk, while others caution that the sharp price moves have occurred without new clinical results.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its Q3 earnings report, with traders weighing the recent rebound against concerns about margins and whether results or guidance can justify high expectations. Speculative SpaceX merger chatter adds to the discussion, while views remain split between a continued rally and a post-earnings pullback.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is in focus after a strong Q3 earnings beat was met with a sharp selloff, as traders weighed a proposed antitrust settlement and a narrower full-year da Vinci procedure-growth outlook. Some see the reaction as excessive given continued business growth, while others view the outlook and settlement as reasons for caution.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels volatile rebound after a sharp semiconductor selloff has drawn attention to JPMorgans upgrade to Neutral and the companys turnaround prospects. Bulls point to potential foundry wins and improving execution, while skeptics question the valuation and durability of the bounce; earnings are also in focus.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept up in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry that heavy data-center spending, debt and financing costs may outpace returns; CoreWeaves debt concerns and Gartners warning about neocloud consolidation add to the pressure. Bulls argue Nebius has stronger finances and can benefit from sustained demand for AI compute, while bears question whether the buildout can be funded profitably; traders are also watching upcoming earnings and hyperscaler capex commentary.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention after a small-cap rebound amid rotation away from tech, with traders pointing to easing yields and reports of a possible U.S.Iran deal that helped lift broader markets. The deal remains unconfirmed, and the community is split between seeing a relief rally and viewing the move as a fragile, headline-driven bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Equity

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 


Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select...

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx...

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)PR NewswireNEW YORK, Sept. 11, 2026Biohaven shares gave up nearly 15% in a single...

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.


BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion.
SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout   

Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim. 


Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead...

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$VTRS" data-symbol-id="VTRS" href="https://stocktwits.com/symbol/VTRS" target="_blank">Viatris</a> agreed on Thursday to buy Pacira BioSciences for $1.65 billion in cash, or $36.50 a share.</li><li>GE HealthCare agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans.</li><li>Biohaven licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical; Alector signed a separate license with Genentech.</li></ul><p>U.S.-listed drugmakers spent the week selling rights or buying products they can already sell. Cash went to approved pain drugs, a factory that makes imaging agents, and two license deals, including one that leaves the American company in charge of its home market.</p><p>The companies did not purchase experimental drug candidates as they did last week when drugmakers, including Novo Nordisk and Novartis, invested in experimental drugs.</p><h2 class="st-heading-2">Viatris Buys A Pain Franchise</h2><p>Viatris (VTRS) agreed on Thursday to buy Pacira BioSciences (PCRX) for $1.65 billion in cash, or $36.50 a share. That was a premium of about 45% to Pacira’s last close.</p><p>Pacira sells Exparel, a long-acting numbing shot used after surgery, and Zilretta, an injection for knee arthritis. Pacira expects Exparel sales of $600 million to $620 million this year. Viatris, which is waiting on a U.S. decision for its own non-opioid pain drug, said the products fit its push into branded medicines and that it would try to sell them in more countries. The deal is expected to close by the end of 2026. Pacira shares closed Thursday at $36.39, up 44%.</p><h2 class="st-heading-2">GE Healthcare Buys The Delivery Network</h2><p>GE HealthCare (GEHC) agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans. Sofie runs 15 manufacturing sites and 21 cyclotrons. The tracers fade within hours, so the plant has to be near the hospital. GE also gets U.S. rights to FAPI-74, an experimental cancer-imaging agent it already controls outside the country. Sofie already makes GE’s heart-scan product Flyrcado. Closing is expected in the first half of 2027.</p><h2 class="st-heading-2">Two Biotechs License Out</h2><p>Biohaven (BHVN) licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical. The package is $80 million at signing and a further $20 million expected within about a year, plus royalties of roughly 20 percent on Ono’s sales in Japan and other Asian markets. Biohaven keeps the United States, Europe, and China. The lead drug, BHV-1300, is in a late-stage study for Graves’ disease.</p><p>Alector (ALEC) signed a separate license with Genentech, the U.S. unit of Roche (RHHBY). Alector gets $100 million upfront and could receive up to $1.17 billion more for AL-050, an experimental enzyme therapy aimed at Parkinson’s and other brain disorders. Genentech gained worldwide rights to develop the AL-050 program. The deal lands three months after GSK (GSK) walked away from an older Alector partnership.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around VTRS and PCRX &nbsp;was in 'bullish' territory over the past 24 hours, while GEHC and BHVN stayed within the 'neutral' territory. Sentiment around ALEC stayed within the 'extremely bullish' territory.</p><p>While VTRS has gained 42% year-to-date, PCRX has added 40%, BHVN 7%, and ALEC 33%. Meanwhile, GEHC has fallen 20%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-sets-new-52-week-high-as-nasdaq-100-reentry-meets-nih-cancer-vaccine-push/cZxGGuoRBnj">MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com</p>

Assortment of multi-colored pills, tablets, and capsules scattering on a vibrant blue surface representing healthcare and medicine. Source: Getty Images

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 

Alector Inc

Biohaven Pharmaceutical Holding Company Ltd

GE HealthCare Technologies Inc

Pacira BioSciences Inc

Viatris Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.81
Prev Close	$11.35
Open	$11.35
Dividend Yield	0.00%
50-Day Moving Average	$13.61
Beta	1.61
Avg. Volume	3.05M
PE Ratio	-2.44

52-Week High	$18.57
52-Week Low	$7.48
Market Capitalization	$1.71B
EPS (Annual)	-$6.86
Price to Book	140.24
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BHVN Fundamentals